Safe management of tacrolimus together with posaconazole in lung transplant patients with cystic fibrosis

Therapeutic Drug Monitoring

Volumn 31, Issue 3, 2009, Pages 396-399

  Berge, Maud ^a   Chevalier, Patrick ^a   Benammar, Mohammed ^a   Guillemain, Romain ^a   Amrein, Catherine ^a   Lefeuvre, Sandrine ^a   Boussaud, Véronique ^a   Billaud, Eliane M ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Cystic fibrosis; Drug interaction; Lung transplantation; Posaconazole; Tacrolimus

Indexed keywords

CYTOCHROME P450 3A4; ITRACONAZOLE; POSACONAZOLE; STEROID; TACROLIMUS; VORICONAZOLE;

ADULT; ARTICLE; ASPERGILLOSIS; CLINICAL ARTICLE; CYSTIC FIBROSIS; DRUG INHIBITION; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HUMAN; LUNG TRANSPLANTATION; MALE; PRESCRIPTION; PRIORITY JOURNAL;

ADULT; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CYSTIC FIBROSIS; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; DRUG MONITORING; DRUG TOXICITY; ENZYME INHIBITORS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ITRACONAZOLE; LUNG TRANSPLANTATION; MALE; MICROBIAL SENSITIVITY TESTS; MYCOSES; PRESCRIPTIONS; PYRIMIDINES; TACROLIMUS; TRIAZOLES;

EID: 67651115757     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31819de6fd     Document Type: Article

References (12)

1. Aperis G, Mylonakis E. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin Investig Drugs. 2006;15:579-602.
2. Keating GM. Posaconazole. Drugs. 2005;65:1553-1567.
3. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance [review]. Clin Pharmacokinet. 2000;38:111-180.
4. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants [review]. Pharmacotherapy. 2006;26: 1730-1744.
5. Hansten PD, Horn JR. Drug Interactions Analysis and Management. Facts
6. Müller C, Arndt M, Queckenberg C, et al. HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases. Mycoses. 2006;49:17-22.
7. Billaud EM, Guillemain R, Tacco F, et al. Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients. Br J Clin Pharmacol. 1998;46:271-274.
8. Billaud EM, Berge M, Guillemain R, et al. Voriconazole therapeutic drug monitoring (TDM) in lung transplanted patients. Presented at: The 16th Congress of the International Society for Human and Animal Mycology (ISHAM); Paris, France. June 25-29, 2006; Abstract O-0008-2006.
9. Dodds Ashley ES, Lewis R, Lewis JS, et al. Pharmacology of systemic antifungal agents. Clin Infect Dis. 2006;43:S28-S39.
10. Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit. 2008;30: 167-172.
11. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327-360.
12. Kearns GL, Crom WR, Karlson KH, et al. Evaluation of drug metabolism in patients with mild cystic fibrosis. Clin Pharmacol Ther. 1996;59: 529-540. and Comparisons. St. Louis, MO: Wolters Kluwer Health, Inc, 2008.